Swiss BioTech Scale-up Mabylon Secures €31.8 Million Funding

The funding includes a €15.9 million capital increase and a convertible loan, primarily from Mabylon’s existing private investors, with significant backing from former Roche management and board members.

“We are very pleased to have closed a CHF 30 million financing agreement in such a challenging global funding environment. This is a strong validation of our approach using human-derived, multi-specific antibodies for the treatment of allergies,“ said Alcide Barberis, PhD, CEO of Mabylon. “We also warmly welcome Dr Thomas Hecht to our Board of Directors. He brings outstanding industry expertise and will help us advance and commercialise our pipeline of best-in-class allergen-neutralising antibodies.”

Founded in 2015, Mabylon is a Swiss biotech company focused on unlocking the therapeutic potential of naturally occurring human antibodies to treat allergies, neurodegenerative diseases and inflammation. Mabylon believes human-derived antibodies offer superior effectiveness compared to those from traditional sources like humanized animal models or artificial libraries.

Read Also - Prosus Gets European Commission Nod For Just Eat Takeaway deal

For example, Mabylon’s antibodies derived from allergic patients target specific disease-related epitopes, enhancing understanding of novel allergenic epitopes and their role in disease progression.

The recent funding will help Mabylon advance its lead program, MY006—a tri-specific antibody that neutralizes peanut allergens—toward completing a Phase Ia/b trial by 2027, aiming to gather robust safety and preliminary efficacy data.

Additionally, the funds will support further development of discovery and preclinical programs, including MY010, a multi-specific antibody targeting the birch Bet v 1 allergen and related tree, fruit, and nut allergens, as well as MY011, designed to treat grass pollen allergies.

At the recent shareholders’ meeting, Dr. Thomas Hecht was elected to Mabylon’s Board of Directors, succeeding Prof. Adriano Aguzzi, whose term ended in June 2025.

“MY006 is a multi-specific anti-allergen antibody for the prophylactic treatment of peanut allergy, an indication with a high unmet medical need. The funds will enable Mabylon to reach clinical proof-of-concept and further advance its early-stage pipeline,” said Gottlieb Keller, Chairman of Mabylon’s Board of Directors. “I would like to thank Prof. Adriano Aguzzi for his contributions to the board and welcome Thomas Hecht as a new board member.”

About Mabylon

Mabylon AG, a Swiss biotech firm, pioneers antibody-based therapies for severe allergies, inflammation and neurological disorders. Using a rapid B-cell screening platform, they identify natural human antibodies with high therapeutic potential. Their lead candidate, MY006, is a first-in-class multispecific antibody targeting the expanding peanut allergy market.